Daidzein and luteolin prevents inflammation in BPH induced rats

Jamia Hamdard, Department of Medical Elementology and Toxicology Page 76 1. Background Benign prostatic hyperplasia (BPH) is a progressive proliferation of prostatic glandular and stromal tissues. BPH is an age related disease and is present in 20% of 40 yrs and 70% of 60 yr old men (Isaacs 1994). Currently, there is no complete effective treatment for BPH. In some severe cases, mostly transurethral resection of the prostate is the only effective intervention available today (Roehrborn 2005). Thus, new therapies are obviously needed. Despite the enormous burden of BPH on public health, its pathogenesis is incompletely understood. To date, we still have no precise knowledge of the cellular and molecular processes underlying the pathogenesis of BPH (Lee and Peehl 2004).